CN116023477A - 新型冠状病毒rbd特异性单克隆抗体和应用 - Google Patents
新型冠状病毒rbd特异性单克隆抗体和应用 Download PDFInfo
- Publication number
- CN116023477A CN116023477A CN202210273152.3A CN202210273152A CN116023477A CN 116023477 A CN116023477 A CN 116023477A CN 202210273152 A CN202210273152 A CN 202210273152A CN 116023477 A CN116023477 A CN 116023477A
- Authority
- CN
- China
- Prior art keywords
- novel coronavirus
- rbd
- monoclonal antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 25
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 26
- 230000014509 gene expression Effects 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 102100031673 Corneodesmosin Human genes 0.000 claims description 8
- 101710139375 Corneodesmosin Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000012827 research and development Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 12
- 239000004005 microsphere Substances 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000012257 pre-denaturation Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
本发明属于单克隆抗体技术领域,具体公开了新型冠状病毒RBD特异性单克隆抗体以及上述新型冠状病毒RBD特异性单克隆抗体的应用。本发明对于新型冠状病毒SARS‑CoV‑2引起疾病的预防、临床治疗和诊断试剂的研发均具有重要的科学意义和应用前景。
Description
技术领域
本发明属于单克隆抗体技术领域,尤其涉及新型冠状病毒RBD特异性单克隆抗体和应用。
背景技术
抗体是由四条多肽链组成的免疫球蛋白分子,四条多肽链包括两条重链(H链)和两条轻链(L 链)。H链由重链可变区(VH)和重链恒定区组成,重链恒定区由三个区CH1、CH2和CH3组成。L 链由L链可变区(VL)和轻链恒定区组成,轻链恒定区由CL区组成。VH和VL可进一步分成称为互补决定区(CDRs)的高变区和称为构架区(FR)交替分布的保守区。
目前研究发现:新型冠状病毒(SARS-CoV-2)具有四种主要的结构蛋白,分别为刺突蛋白(S 蛋白)、核衣壳蛋白(N蛋白)、膜蛋白(M蛋白)和包膜蛋白(E蛋白),其中S蛋白有两个亚基: S1和S2,受体结合位点(RBD)位于S1亚基上,其主要功能是识别宿主细胞表面受体,介导与宿主细胞的融合。
目前针对新发病原体COVID-19尚无特效药物针对性治疗,疫苗研发尚需时日。近期治愈出院的患者血浆中含有高浓度特异性的抗原中和抗体,输入患者体内后,可以中和新冠病原体,介导有效的免疫反应,因此利用恢复期血浆有望为救治感染新型冠状病毒的患者提供有效的治疗手段,降低死亡率,保障患者生命安全。
申请公开号为CN111303280A的中国发明专利申请公开了一种高中和活性抗SARS-CoV-2全人源单克隆抗体,上述专利提供的是识别区域为S1非RBD区的全人源单克隆抗体,但是由于新型冠状病毒入侵宿主细胞是通过RBD与宿主细胞的ACE2结合,所以上述专利获得的全人源单克隆抗体对病毒的阻断效果有限,并且上述专利是通过标记浆细胞而获得抗体cDNA,但是与浆细胞相比,是记忆B细胞活化后迅速做出反应,所以记忆B细胞能够引发比初次反应更快,也更强烈的体液免疫反应,而浆细胞所引发的体液免疫反应有限。
发明内容
本发明的目的在于提供一种针对RBD,并且能够引发更强烈体液免疫反应的新型冠状病毒RBD 特异性单克隆抗体和应用。
为了达到上述目的,本发明提供了新型冠状病毒RBD特异性单克隆抗体,具体的,抗体的重链氨基酸序列如SEQ ID NO:1所示;轻链氨基酸序列如SEQ ID NO:2所示(单抗1-CQTS113)。重链氨基酸序列还可如SEQ ID NO:3所示;轻链氨基酸序列还可如SEQ ID NO:4所示(单抗2-CQTS114)。重链氨基酸序列还可如SEQ ID NO:5所示;轻链氨基酸序列还可如SEQ ID NO:6所示(单抗3-CQTS115)。重链氨基酸序列还可如SEQ ID NO:7所示;轻链氨基酸序列还可如SEQ ID NO:8所示(单抗4-CQTS116)。重链氨基酸序列还可如SEQ ID NO:9所示;轻链氨基酸序列还可如SEQ ID NO:10所示(单抗5-CQTS117)。重链氨基酸序列还可如SEQID NO:11所示;轻链氨基酸序列还可如SEQ ID NO:12所示(单抗6-CQTS118)。重链氨基酸序列还可如SEQ ID NO:13所示;轻链氨基酸序列还可如SEQ ID NO:14所示(单抗7-CQTS119)。重链氨基酸序列还可如SEQ ID NO:15所示;轻链氨基酸序列还可如SEQ ID NO:16所示(单抗8-CQTS120)。重链氨基酸序列还可如SEQ ID NO:17 所示;轻链氨基酸序列还可如SEQ IDNO:18所示(单抗9-CQTS121)。重链氨基酸序列还可如SEQ ID NO:19所示;轻链氨基酸序列还可如SEQ ID NO:20所示(单抗10-CQTS122)。重链氨基酸序列还可如SEQ ID NO:21所示;轻链氨基酸序列还可如SEQ ID NO:22所示(单抗11-CQTS123)。重链氨基酸序列还可如SEQID NO:23所示;轻链氨基酸序列还可如SEQ ID NO:24所示(单抗 12-CQTS124)。重链氨基酸序列还可如SEQ ID NO:25所示;轻链氨基酸序列还可如SEQ ID NO:26 所示(单抗13-CQTS125)。重链氨基酸序列还可如SEQ ID NO:27所示;轻链氨基酸序列还可如SEQ ID NO:28所示(单抗14-CQTS126)。重链氨基酸序列还可如SEQ ID NO:29所示;轻链氨基酸序列还可如SEQ ID NO:30所示(单抗15-CQTS127)。重链氨基酸序列还可如SEQ ID NO:31所示;轻链氨基酸序列还可如SEQ ID NO:32所示(单抗16-CQTS128)。重链氨基酸序列还可如SEQ IDNO:33 所示;轻链氨基酸序列还可如SEQ ID NO:34所示(单抗17-CQTS129)。重链氨基酸序列还可如SEQ ID NO:35所示;轻链氨基酸序列还可如SEQ ID NO:36所示(单抗18-CQTS130)。重链氨基酸序列还可如SEQ ID NO:37所示;轻链氨基酸序列还可如SEQ ID NO:38所示(单抗19-CQTS131)。重链氨基酸序列还可如SEQ ID NO:39所示;轻链氨基酸序列还可如SEQ ID NO:40所示(单抗 20-CQTS132)。
本发明还提供了上述新型冠状病毒RBD特异性单克隆抗体,在制备检测或诊断SARS-CoV-2试剂或疫苗或药物中的应用,其中药物包括新型冠状病毒RBD特异性单克隆抗体和药学上可接受的赋形剂、稀释剂或载体;还提供了编码上述新型冠状病毒RBD特异性单克隆抗体的核酸分子;还提供了含有上述核酸分子的表达盒、重组载体、重组菌或转基因细胞系;还提供了上述表达盒、重组载体、重组菌或转基因细胞系在制备产品中的应用。
本发明还提供了产品,包括上述新型冠状病毒RBD特异性单克隆抗体;产品用途如下(b1)- (b4)中的任一种:(b1)结合新型冠状病毒SARS-CoV-2;(b2)检测结合新型冠状病毒SARS-CoV-2; (b3)结合新型冠状病毒SARS-CoV-2的S蛋白;(b4)检测新型冠状病毒SARS-CoV-2的S蛋白。
优选的,上述新型冠状病毒RBD特异性单克隆抗体均通过分选RBD特异性记忆B细胞,再通过RBD特异性记忆B细胞的mRNA获得抗体可变区cDNA。
本发明的原理和有益效果在于:
(1)本发明提供的单克隆抗体具有RBD特异性,与针对S1非RBD区的单可隆抗体相比,本发明提供的单克隆抗体与RBD结合,为抗体药物筛选,诊断、预防和治疗新冠肺炎提供了更加广泛的应用价值。
(2)本发明提供的单克隆抗体是通过分选RBD特异性记忆B细胞而得到,与通过分选浆细胞的现有技术相比,本发明制备的单克隆抗体能够引发更强烈的体液免疫反应。另外,本发明只针对 RBD特异性记忆B细胞进行后续RT-PCR、巢式PCR和抗体功能分析,大大提高了单克隆抗体与RBD 特异性结合能力。
附图说明
图1为采用流式细胞仪分析RBD特异性记忆B细胞的细胞分选图;
图2为采用流式细胞仪分析RBD特异性记忆B细胞的细胞分选图;
图3为RBD特异性检测结果图。
具体实施方式
下面将结合本发明实施例的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本实施例提供一种新型冠状病毒RBD特异性单克隆抗体,重链氨基酸序列如SEQID NO:1所示;轻链氨基酸序列如SEQ ID NO:2所示。
本实施例还提供了上述新型冠状病毒RBD特异性单克隆抗体,在制备检测或诊断SARS-CoV-2 试剂或药物中的应用。
在实际生产时,可以采用本实施例得到RBD特异性单克隆抗体制备核酸分子,或者制备包含该核酸分子的表达盒、重组载体、重组菌或转基因细胞系,或者制备药物组合物,该药物组合物包括上述新型冠状病毒RBD特异性单克隆抗体和药学上可接受的赋形剂、稀释剂或载体。
在应用时,本实施例得到RBD特异性单克隆抗体制备的相关产品,可具有如下(b1)-(b4)中的任一种的用途:(b1)结合新型冠状病毒SARS-CoV-2;(b2)检测结合新型冠状病毒SARS-CoV-2; (b3)结合新型冠状病毒SARS-CoV-2的S蛋白;(b4)检测新型冠状病毒SARS-CoV-2的S蛋白。
实施例2-20
实施例2-20与实施例1的区别在于:RBD特异性单克隆抗体的氨基酸序列不同,实施例2-20的氨基酸序列如下表所示:
以上实施例1-20所提供的RBD特异性单克隆抗体均通过以下方法得到:首先从新冠肺炎康复患者的外周血中分选得到单个RBD特异性记忆B细胞,然后获得RBD特异性记忆B细胞的mRNA,再通过RT-PCR和巢式PCR构建抗体可变区基因表达盒,再将抗体可变区基因表达盒转导入293T细胞表达抗体并收集上清,用ELISA法检测上清的RBD特异性,筛选得到RBD特异性单克隆抗体。
具体包括以下步骤:
S1、采集若干名新冠肺炎康复患者外周血,分离得到PBMC,在-80℃的冰箱中冻存备用。
S2、首先采用去死细胞染料(Dead Dye)去除S1得到的PBMC的死细胞,然后采用CD19、mIg-G、 mIg-D和S-RBD对PBMC中活的RBD特异性并且结合能力高的记忆B细胞染色标记,筛选出针对 RBD特异性记忆B细胞;使用流式细胞分选仪将特异性记忆B细胞分选到96孔板上,每个孔内有一个特异性记忆B细胞,在-80℃的冰箱中冻存备用。
具体的,本实施例优选的Dead Dye染色时的浓度范围为1-2μg/mL,本实施例优选Dead Dye染色时的浓度为1.5μg/mL;CD19为Biolegend生产的B细胞标记物,染色时的浓度范围为1-2μg/mL,本实施例优选CD19染色时的浓度为1.5μg/mL。mIg-G为Biolegend生产的B细胞标表面受体,染色时的浓度范围为1-2μg/mL,本实施例优选mIg-G染色时的浓度为1.5μg/mL;mIg-D为Biolegend生产的B细胞表面受体,染色时的浓度范围为1-2μg/mL,本实施例优选mIg-D染色时的浓度为 1.5μg/mL;S-RBD为sinobiological生产的新型冠状病毒是蛋白受体结构域,染色时的浓度范围为 1-2μg/mL,本实施例优选S-RBD染色时的浓度为1.5μg/mL。
通过流式细胞仪分选RBD特异性记忆B细胞的,通过CD19、mIg-G、mIg-D和S-RBD对PBMC 的细胞分选得到对S-RBD具有特异性记忆B细胞的细胞分选图如图1和图2所示,其中图2中的Batch ID 0428、0505、0522、0528是筛选批次。本实施例采用CD19、mIg-G、mIg-D和S-RBD筛选出针对RBD特异性记忆B细胞的原理在于:将PBMC用去死细胞染料(Dead Dye)、B细胞标记物CD19、记忆B细胞标记物mIg-G阳性和mIg-D阴性以及RBD特异性IgG表达的记忆B细胞进行染色,然后使用流式细胞分析仪将细胞群中CD19细胞群划分出来,再通过从CD19阳性细胞群中划分 mIg-G+mIg-D-细胞群,再从mIg-G+mIg-D-细胞群划分RBD阳性的记忆B细胞,再通过流式细胞分选仪将RBD阳性的记忆B细胞进行分选。
S3、分选得到单个RBD特异性记忆B细胞的mRNA,采用RT-PCR扩增获得抗体可变区cDNA。具体的,使用RT-PCR扩增抗体可变区cDNA时,本实施例所设计的引物的引物前段设计有通用Leader (参见引物序列表一和引物序列表二),有效提高了抗体基因的扩增率。
S4、采用巢式PCR扩增S1-S3得到的抗体可变区cDNA,构建抗体可变区基因表达盒。
S3和S4总共通过以下六部分进行:(1)提取RBD特异性记忆B细胞的mRNA;(2)单个细胞mRNA逆转录(RT);(3)加G尾(TDT);(4)第一轮PCR(1st PCR);(5)第二轮PCR (2ndPCR);(6)BCR-ORF PCR扩增构建基因表达盒;(7)CMV、WPRE-γ/κ/l片段扩增及CMV、 BCR-Vγ/κ/l((6)的产物)、WPRE-γ/κ/l重叠PCR(Overlap PCR)预连接;(8)BCR-γORF、 BCR-κORF、BCR-lPCR扩增。
各部分反应液配制及反应条件如下:
(1)采用DynabeadsTM mRNA DIRECTTM Purification Kit(ThermoFisherscientific)进行单细胞 mRNA提取,具体包括以下步骤:
①离心:从-80℃冰箱中取出分选有单个RBD特异性记忆B细胞的96孔板后,600×g离心30s,使细胞离心于孔底部;
②清洗:将Dynabeads oligo(dT)25微球瓶取出后涡旋混匀,按照2μl/孔吸取足量微球,放置于磁铁块上,静置30s,弃上清,用500μl的Lysis Buffer重悬;
③配制:按照9μl/孔Lysis Buffer加入到50mL的离心管中,将上述500μl微球悬液加入其中,用枪吹匀;
④分装:用八连管分装微球,随后采用排枪将其按照9μl/孔加入到细胞板中;
⑤润洗:96孔板贴膜,随后润洗管壁四周,共2个循环;
⑥孵育:室温静置5min,使RBD特异性记忆B细胞的mRNA充分释放并结合到微球上,孵育结束后,600×g瞬时离心,使微球离心于孔底部。将96孔板放置于DynaMagTM-96sideMagnet磁板上,用排枪吸弃上清;
⑦Wash A清洗:按照8μl/孔加入Washing Buffer A,来回走板7-8次,使微球充分洗涤,弃上清;
⑧Wash B清洗:按照8μl/孔加入Washing Buffer B,来回走板7-8次,使微球充分洗涤,弃上清,随后按照10μl/孔加入预先配制的逆转录(RT)反应液。试剂配制及反应条件如下述(2)描述。
(2)逆转录(RT)(10μl体系)
所需配制的试剂如下表1所示:
试剂名称 | 体积 |
<![CDATA[DEPC-H<sub>2</sub>O]]> | 4.5μl |
5×primerscript Buffer | 2.0μl |
2.5mM dNTP | 2.0μl |
RNase Inhibitor | 1μl |
Sample | beads |
PrimerScriptⅡRTase | 0.5μl |
总体积 | 10μl |
反应条件:42℃for 60min(每20min混合一次);
反应结束后,600×g瞬时离心96孔板,然后将96孔板放置于DynaMagTM-96sideMagnet磁板上,用排枪吸弃上清,随后按照10μl/孔加入预先配制的TDT反应液,试剂配制及反应条件如下述(3)描述。
(3)加G尾(TDT)(10μl体系)
所需配制的试剂如下表2所示:
反应条件:37℃for 40min(每20min混合一次)。
反应结束,600×g瞬时离心96孔板,然后将其放置于DynaMagTM-96side Magnet磁板上,用排枪吸弃上清,随后按照10μl/孔加入预先配制的第一轮PCR(1st PCR)反应液,试剂配制及反应条件如下述(4)描述。
(4)1st PCR(10μl体系)(引物序列参见引物序列表)
所需配制的试剂如下表3所示:
试剂名称 | 体积 |
<![CDATA[H<sub>2</sub>O]]> | 1.9μl |
2×GC Buffer | 5μl |
2.5mM dNTP | 1μl |
FP:AP3-dC(10μM) | 0.5μl |
RP1:Cg-1st(10μM) | 0.5μl |
RP2:Ck-1st(10μM) | 0.5μl |
RP3:CI-RT(10μM) | 0.5μl |
PrimesTAR | 0.1μl |
sample | beads |
总体积 | 10μl |
基于PCR原理,1st PCR的实验反应条件为:①95℃预变性3min;②95℃变性15sec,60℃退火5sec,72℃延伸1min,30-35cycles,本实施例优选30cycles;③72℃循环外延伸5min,4℃保存。
(5)第二轮PCR(2nd PCR)(10μl体系)(引物序列参见引物序列表一和引物序列表二)
所需配制的试剂如下表4所示:
基于PCR原理,2nd PCR的实验反应条件为:①95℃预变性3min;②95℃变性15sec,60℃退火5s, 72℃延伸1min,30-35cycles,本实施例优选35cycles;72℃循环外延伸5min,4℃保存。
PCR结束后:每孔取4μl进行1.5%琼脂糖凝胶电泳。将Gamma链与Kappa链或Lamada链配对的细胞孔送测序。
(6)抗体表达盒(BCR-ORF)的扩增和构建
PCR扩增启动子区(CMV启动子)、WPRE-γ(抗体gamma链)和WPRE-κ(抗体kappa链),PCR扩增体系如下表5所示:
PCR扩增条件为:①95℃预变性3min;②95℃变性15sec,56℃退火15sec,72℃延伸1min, 30cycles;③72℃循环外延伸5min,12℃保存。
(7)CMV、WPRE-γ/κ/l片段扩增及CMV、BCR-Vγ/κ/l、WPRE-γ/κ/l重叠PCR(Overlap PCR) 预连接
实验体系如下表6所示:
PCR扩增条件为:95℃预变性3min;95℃变性15sec,50℃退火15sec,72℃延伸1.5min,10cycles; 72℃循环外延伸5min,12℃保存。
(8)BCR-γORF、BCR-κORF、BCR-l PCR扩增
实验体系如下表7所示:
PCR扩增程序:95℃预变性3min;95℃变性15sec,58℃退火15sec,72℃延伸1.5min,30cycles; 72℃循环外延伸5min,12℃保存。
BCR-γORF和BCR-κ/ORF乙醇沉淀:BCR-γORF和BCR-κORF的PCR产物各取30μl置于8 连管中,再加入120μl无水乙醇,6μl醋酸钠溶液,充分混匀,-80℃静置30min;10000rpm,离心20min,弃上清,依次用200μl的70%乙醇和无水乙醇各漂洗一次,于56℃乙醇充分挥发,加入40μl无菌水,振荡,使沉淀充分溶解,检测抗体可变区基因的浓度。
S3和S4所用到的Leader引物参见如下的引物序列表一:
S3和S4所用到的所用到J-region引物参见如下的引物序列表二:
primer ID | sequence |
IGHJ_01 | GATGGGCCCTTGGTGGAGGGTGAGGAGACGGTGACCAGGGTGCCCTGGCCCCAGT |
IGHJ_02 | GATGGGCCCTTGGTGGAGGGTGAGGAGACAGTGACCAGGGTGCCACGGCCCCAGA |
IGHJ_03 | GATGGGCCCTTGGTGGAGGGTGAAGAGACGGTGACCATTGTCCCTTGGCCCCAGA |
IGHJ_04 | GATGGGCCCTTGGTGGAGGGTGAGGAGACGGTGACCGTGGTCCCTTGCCCCCAGA |
IGKJ_01 | GATGGTGCAGCCACAGTTCGTTTGATTTCCACCTTGGTCCCTTGGCCGAACGTCC |
IGKJ_02 | GATGGTGCAGCCACAGTTCGTTTGATTTCCACCTTGGTCCCTTGGCCGAACGTCC |
IGKJ_03 | GATGGTGCAGCCACAGTTCGTTTGATATCCACTTTGGTCCCAGGGCCGAAAGTGA |
IGKJ_04 | GATGGTGCAGCCACAGTTCGTTTGATCTCCACCTTGGTCCCTCCGCCGAAAGTGA |
IGKJ_05 | GATGGTGCAGCCACAGTTCGTTTAATCTCCAGTCGTGTCCCTTGGCCGAAGGTGA |
IGLJ_01 | GGGGCAGCCTTGGGCTGACCTAGGACGGTGACCTTGGTCCCAGTTCCGAAGACAT |
IGLJ_02 | GGGGCAGCCTTGGGCTGACCTAGGACGGTCAGCTTGGTCCCTCCGCCGAATACCA |
IGLJ_03 | GGGGCAGCCTTGGGCTGACCTAAAATGATCAGCTGGGTTCCTCCACCAAATACAA |
IGLJ_04 | GGGGCAGCCTTGGGCTGACCTAGGACGGTCAGCTCGGTCCCCTCACCAAACACCC |
IGLJ_05 | GGGGCAGCCTTGGGCTGACCTAGGACGGTCAGCTCCGTCCCCTCACCAAACACCC |
IGLJ_06 | GGGGCAGCCTTGGGCTGACCGAGGACGGTCACCTTGGTGCCACTGCCGAACACAT |
IGLJ_07 | GGGGCAGCCTTGGGCTGACCGAGGACGGTCAGCTGGGTGCCTCCTCCGAACACAG |
IGLJ_08 | GGGGCAGCCTTGGGCTGACCGAGGGCGGTCAGCTGGGTGCCTCCTCCGAACACAG |
S5、将S4得到的抗体可变区基因表达盒转导入293T细胞48小时内表达抗体并收集上清,用ELISA法检测上清的RBD特异性,筛选RBD特异性全人源单克隆抗体。
(A)使用PBS稀释抗原(终浓度2μg/mL),10μl/孔,包被384孔ELISA板4℃过夜或37℃包被 2h(本实施例优选4℃过夜)。NOTE:加完后瞬时离心保证液体在底部。
实验体系如下表8所示:
试剂名称 | 货号 | 原浓度 | 终浓度 | 稀释比 |
SARS-COV-2RBD | Cat:40592-V08H | 200μg/mL | 2μg/mL | 1:100 |
Goat pab to Hu IgG-ALP | Cat:ab97221 | 1mg/mL | 2μg/mL | 1:500 |
(B)配制PBST(0.05% Tween 20,Cat#TB220):1L的PBS加入0.5mL的Tween 20;
PBST机洗板子(Thermoscientific wellwash versa)或者手洗(机洗完的板子依然要手动拍板/使用微孔板离心机(MPC-P25)离心1min,使板子看不见有水和气泡)。
封闭:80μl的5%BSA(BioFroxx,Cat.NO:4240GR100)(PBST配制)加入上述洗好的板子里,放置于37℃的孵育箱孵育1h。PBST机洗板子或者手洗。
(C)加样及标准品。其中,标准品:10μl/well原浓度1μg/mL,梯度稀释为250ng/mL、125ng/mL、 62.5ng/mL、31.25ng/mL、15.63ng/mL、7.81ng/mL、3.9ng/mL和1.95ng/mL。(封闭液稀释);样品:转染抗体基因的细胞上清液。阴性对照/空白孔:封闭液10μl/well。
在37℃孵育30min。PBST机洗板子或者手洗。
(D)加二抗,加入的浓度为10μl/well,然后在37℃下孵育30min。
实验体系如下表9所示:
二抗名称 | 货号 | 原浓度 | 终浓度 | 稀释比 |
goat-anti-human IgG-ALP | A18808 | 1.5mg/ml | 0.3μg/ml | 1:5000 |
Goat pab to Hu IgG-ALP | Ab98532 | 0.5mg/ml | 0.25μg/ml | 1:2000 |
PBST机洗板子或者手洗。10μl/well的PNPP(对硝基苯磷酸二钠),使用(Thermoscientific Muttiskan GO)检测5min、10min、15min、20min、25min、30min、35min、40min、45min、50min、55min和 60min的OD(450mm)值。50mg的PNPP粉末(Thermo,Prod#34045)+40mL的ddH2O+10mL的 Diethanol aminesubstrate Buffer(5X),PNPP避光4℃储存。
实验结果如图3所示,OD值大于0.1为阳性。
以上所述仅为本发明的优选实施例,对本发明而言仅是说明性的,而非限制性的;本领域普通技术人员理解,在本发明权利要求所限定的精神和范围内可对其进行许多改变,修改,甚至等效变更,但都将落入本发明的保护范围内。
Claims (8)
1.新型冠状病毒RBD特异性单克隆抗体,其特征在于,重链氨基酸序列还可如SEQ IDNO:3所示;轻链氨基酸序列还可如SEQ ID NO:4所示。
2.根据权利要求1所述的新型冠状病毒RBD特异性单克隆抗体,其特征在于,重链氨基酸序列还可如SEQ ID NO:5所示;轻链氨基酸序列还可如SEQ ID NO:6所示。
3.根据权利要求1所述的新型冠状病毒RBD特异性单克隆抗体,其特征在于,重链氨基酸序列如SEQ ID NO:1所示;轻链氨基酸序列如SEQ ID NO:2所示。
4.根据权利要求1-3中任一权利要求所述的新型冠状病毒RBD特异性单克隆抗体,其特征在于,均通过分选RBD特异性记忆B细胞,再通过RBD特异性记忆B细胞的mRNA获得抗体可变区cDNA。
5.根据权利要求1-3中任一权利要求所述的新型冠状病毒RBD特异性单克隆抗体,其特征在于,在制备检测或诊断SARS-CoV-2试剂或药物中的应用,其中药物包括权利要求1-3任一权利要求所述的新型冠状病毒RBD特异性单克隆抗体和药学上可接受的赋形剂、稀释剂或载体。
6.编码权利要求1-3中任一权利要求所述的新型冠状病毒RBD特异性单克隆抗体的核酸分子。
7.含有权利要求6所述核酸分子的表达盒、重组载体、重组菌或转基因细胞系。
8.权利要求7所述的表达盒、重组载体、重组菌或转基因细胞系在制备产品中的应用,其特征在于,产品用途如下(b1)-(b4)中的任一种:(b1)结合新型冠状病毒SARS-CoV-2;(b2)检测新型冠状病毒SARS-CoV-2;(b3)结合新型冠状病毒SARS-CoV-2的S蛋白;(b4)检测新型冠状病毒SARS-CoV-2的S蛋白。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210273152.3A CN116023477A (zh) | 2020-08-19 | 2020-08-19 | 新型冠状病毒rbd特异性单克隆抗体和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010839226.6A CN111909260B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体和应用 |
CN202210273152.3A CN116023477A (zh) | 2020-08-19 | 2020-08-19 | 新型冠状病毒rbd特异性单克隆抗体和应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010839226.6A Division CN111909260B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116023477A true CN116023477A (zh) | 2023-04-28 |
Family
ID=73278293
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210272383.2A Active CN115304671B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体及其应用 |
CN202210273152.3A Pending CN116023477A (zh) | 2020-08-19 | 2020-08-19 | 新型冠状病毒rbd特异性单克隆抗体和应用 |
CN202010839226.6A Active CN111909260B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体和应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210272383.2A Active CN115304671B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体及其应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010839226.6A Active CN111909260B (zh) | 2020-08-19 | 2020-08-19 | 新冠病毒rbd特异性单克隆抗体和应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN115304671B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7116256B1 (ja) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗sars-cov-2-スパイク糖タンパク質抗体および抗原結合断片 |
CR20220660A (es) | 2020-06-03 | 2023-02-17 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 |
CN116710555A (zh) * | 2020-09-14 | 2023-09-05 | 南京诺唯赞生物科技股份有限公司 | 针对sars-cov-2的中和抗体 |
CN114685652B (zh) * | 2020-12-31 | 2023-11-03 | 中国科学院分子细胞科学卓越创新中心 | 针对SARS-CoV-2和SARS-CoV的全人广谱交叉中和抗体及其应用 |
CN114716541B (zh) * | 2021-01-05 | 2023-07-21 | 中国科学院分子细胞科学卓越创新中心 | 抗冠状病毒的全人广谱中和抗体76e1及其应用 |
US20240158477A1 (en) * | 2021-01-27 | 2024-05-16 | Bioduro (Jiangsu) Co., Ltd. | Antibody against sars-cov-2 |
CN114805556A (zh) * | 2021-01-29 | 2022-07-29 | 中国科学院上海巴斯德研究所 | 一种针对SARS-CoV-2病毒的中和性抗体 |
CN115109150B (zh) * | 2021-01-31 | 2024-06-25 | 中南大学湘雅医院 | 新型冠状病毒单克隆抗体xy10及其应用 |
WO2022179561A1 (en) * | 2021-02-24 | 2022-09-01 | The University Of Hong Kong | Neutralizing antibodies against covid-19 and methods of use thereof |
CN113651884B (zh) * | 2021-05-25 | 2022-08-26 | 中国科学院微生物研究所 | 人源化抗SARS-CoV-2单克隆抗体及其应用 |
TW202337497A (zh) | 2022-02-18 | 2023-10-01 | 中國大陸商重慶明道浩悅生物科技有限公司 | 鼻內調配物及抗sars-cov-2棘蛋白抗體 |
CN116041494A (zh) * | 2022-12-12 | 2023-05-02 | 首都医科大学 | 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10358497B2 (en) * | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
CN111153991A (zh) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | 一种人SARS-CoV-2单克隆抗体及其制备方法和应用 |
GB202003632D0 (en) * | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
CN111303280B (zh) * | 2020-03-22 | 2022-01-07 | 中国人民解放军军事科学院军事医学研究院 | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 |
CN111474345A (zh) * | 2020-03-25 | 2020-07-31 | 北京博奥森生物技术有限公司 | 一种SARS-CoV-2抗体检测方法 |
CN111537743B (zh) * | 2020-04-03 | 2022-05-03 | 广州医科大学附属第一医院(广州呼吸中心) | SARS-CoV-2新冠病毒抗体检测试剂盒 |
RU2723008C9 (ru) * | 2020-05-19 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Способ получения штамма клеток яичника китайского хомячка, продуцента рекомбинантного белка RBD вируса SARS-CoV-2, штамм клеток яичника китайского хомячка, продуцент рекомбинантного белка RBD вируса SARS-CoV-2, способ получения рекомбинантного белка RBD вируса SARS-CoV-2, тест-система для иммуноферментного анализа сыворотки или плазмы крови человека и ее применение |
-
2020
- 2020-08-19 CN CN202210272383.2A patent/CN115304671B/zh active Active
- 2020-08-19 CN CN202210273152.3A patent/CN116023477A/zh active Pending
- 2020-08-19 CN CN202010839226.6A patent/CN111909260B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111909260A (zh) | 2020-11-10 |
CN115304671B (zh) | 2023-10-17 |
CN115304671A (zh) | 2022-11-08 |
CN111909260B (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115304671B (zh) | 新冠病毒rbd特异性单克隆抗体及其应用 | |
CN116813760B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN114920833B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN111925440B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN115925900B (zh) | 新型冠状病毒rbd特异性单克隆抗体和应用 | |
CN111925444B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN114989293B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN111925441B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN111925443B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 | |
CN115340602B (zh) | 新冠病毒rbd特异性单克隆抗体和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |